Building on the Strategic Framework published in 2021, this new document explains how it should be used. It includes a maturity/capability model to help companies identify how to develop so they can increase their maturity/capability level for any of the five strategic objectives. It is based on shared ‘real-world evidence’ from members who have contributed to how they achieve the level they are at with the people (organizations), systems (technologies) and process (operating procedures) they have invested in.
supply chain
Viewing related articles
Supply chain constraints benchmarking survey
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, POI - Supply Chain to Patient, Supply Chain to Patient
This BioPhorum member only survey explores the challenges of the internal supply chain and the impact they are having on the business. One key theme that appeared to be emerging is that internal resource is a constraint within the supply chain for many companies.
Long range planning – the final frontier, the audacious goal
Nov 2022 | Deliverables Report, Long Range Planning, POI - Supply Partner, Publication, Supply Partner
This paper summarizes the industry position and aims to start a strategic discussion on this situation. It will help ensure we have a common language and understanding across industry. Looking ahead, we will emphasize shared learning, best practices, and retrospective investigations to improve long-range planning processes
Current and near-future bioprocess supply situation and trends post COVID-19
Oct 2022 | COVID 19, Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Partner
This paper provides an overview of the current and near-future bioprocess supply situation and trends. This research provides insights into how the industry has adjusted as the Pandemic begins to abate.
On time in full (OTIF) high level guidance
Jul 2022 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Chain Quality Management, Supply Partner
This paper provides an introduction and a high-level view of on time in full (OTIF) so that when we use the acronym, we know how it is calculated and are all using it in the same way. It examines detail on the components of ‘Actual orders delivered’ and ‘Expected orders to be delivered’ and talks about the information included, actions to take and gives tips on how to best use each component.Â
Biopharmaceutical manufacturing industry inbound supply chain strategic framework
Nov 2021 | COVID 19, Deliverable, POI - Supply Partner, Publication, Supply Partner
The biopharmaceutical manufacturing industry inbound supply chain strategic framework identifies the key five strategic objectives that will help drive operational excellence and improvements to solve some of the most important inbound supply chain issues for the industry over the next 2–5-years.
Supply chain mapping: A best practice for the biopharma industry
May 2018 | COVID 19, POI - Supply Partner, Supply Partner
The complexity of the support networks needed to deliver biopharma products, makes good supply chain mapping (SCM) essential to ensure reliable drug product supply. This is especially the case given the impact that natural disasters, adverse weather and politics can have on supply chain security.
This guide from the Supply Chain Mapping workstream can be tailored to the needs of both suppliers and manufacturers and helps them map and master supply chain risk.  The guide details reasons why companies should adopt the approach, an implementation model, a standardized questionnaire to collate and manage basic supplier data and a maturity model against which a company can assess its own level of supply chain mapping and understanding.
Raw materials: Patient-centric requirements for the supply of raw materials
Jun 2015 | Drug Substance, POI - Supply Partner, Raw materials, Supply Partner
Raw material variability and control in the supply chain are important matters for the biopharmaceutical industry. The industry is still working to align the supply performance with biopharma’s needs. More still needs to be done to understand, monitor and control of raw materials. Patient well-being is best assured by reducing or eliminating variability of the finished drug product, and this can be achieved, in part by targeted reduction and/or elimination of variation in raw materials. This paper identifies ten areas of practice endorsed by leading global biopharmaceutical manufacturers to start to address and reduce raw material variation through our supply chains.